Retrospective analysis of adjuvant chemotherapy for curatively resected gastric cancer
AIM:To determine the efficacy of adjuvant chemotherapy for gastric cancer in clinical practice,a retrospective analysis was conducted in a high-volume Chinese cancer center.METHODS:Between November 1995 and June 2007,a total of 423 gastric or esophagogastric adenocarcinoma patients who did(Arm A,n=3...
Gespeichert in:
| Veröffentlicht in: | World journal of gastroenterology : WJG 2014-03, Vol.20 (12), p.3356-3363 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3363 |
|---|---|
| container_issue | 12 |
| container_start_page | 3356 |
| container_title | World journal of gastroenterology : WJG |
| container_volume | 20 |
| creator | Deng, Wei Wang, Qi-Wei Zhang, Xiao-Tian Lu, Ming Li, Jie Li, Yan Gong, Ji-Fang Zhou, Jun Lu, Zhi-Hao Shen, Lin |
| description | AIM:To determine the efficacy of adjuvant chemotherapy for gastric cancer in clinical practice,a retrospective analysis was conducted in a high-volume Chinese cancer center.METHODS:Between November 1995 and June 2007,a total of 423 gastric or esophagogastric adenocarcinoma patients who did(Arm A,n=300)or did not(Arm S,n=123)receive radical gastrectomy followed by postoperative chemotherapy were enrolled in this retrospective analysis.In Arm A,monotherapy(fluoropy rimidines,n=25),doublet(platinum/fluoropyrimidines,n=164),or triplet regimens[docetaxel/cisplatin/5FU(DCF),or modified DCF,epirubicin/cisplatin/5FU(ECF)or modified ECF,etoposide/cisplatin/FU,n=111]were administered.Disease-free survival(DFS)and overall survival(OS)were compared between the two arms.A subgroup analysis was carried out in Arm A.A multivariate analysis of prognostic factors was conducted.RESULTS:Stage?Ⅰ,ⅡandⅢcancers accounted for9.7%,35.7%and 54.6%of the cases,respectively,according to the American Joint Committee on Cancer(AJCC)staging system,7th edition.Only 178(42.1%)patients had more than 15 lymph nodes harvested.Hazard ratio estimates for Arm A compared with Arm S were 0.47(P<0.001)for OS and 0.59(P<0.001)for DFS.The 5-year OS rate was 52%in Arm A vs36%in Arm S(P=0.01);the adverse events in Arm A were mild and easily controlled.Ultimately,73 patients(26.5%)who received doublet or triplet regimens switched to monotherapy with fluoropyrimidines.The OS and DFS did not differ between monotherapy and the combination regimens,however,both were statistically improved in the subgroup of patients who were switched to monotherapy with fluoropyrimidines after doublet or triplet regimens as well as patients who received≥8 cycles of chemotherapy.CONCLUSION:In clinical practice,platinum/fluoropyrimidines with adequate treatment duration is recommended for stageⅡ/Ⅲgastric cancer patients accordingto the 7th edition of the AJCC staging system after curative gastrectomyeven with limited lymphadenectomy. |
| doi_str_mv | 10.3748/wjg.v20.i12.3356 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3964407</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cqvip_id>90888889504849524950485149</cqvip_id><sourcerecordid>24696615</sourcerecordid><originalsourceid>FETCH-LOGICAL-c440t-ee64509417e8209fa5bdadce9dab9dcf4904f5d22eabc958e6f963ba33e836783</originalsourceid><addsrcrecordid>eNpVkF1LwzAUhoMobk7vvZL8gc40X21uBBl-gSCIehtO09OuY2tn0k32783cHJqbEzjv8yY8hFymbCwymV9_zerxmrNxk_KxEEofkSHnqUl4LtkxGaaMZYkRPBuQsxBmjPEY4qdkwKU2WqdqSD5esfddWKLrmzVSaGG-CU2gXUWhnK3W0PbUTXHR9VP0sNzQqvPUrTxs4_MN9RgiiiWtIfS-cdRB69Cfk5MK5gEv9nNE3u_v3iaPyfPLw9Pk9jlxUrI-QdRSMSPTDHPOTAWqKKF0aEooTOkqaZisVMk5QuGMylFXRosChMBc6CwXI3Kz612uigVGsu09zO3SNwvwG9tBY_9v2mZq625thdHxB1ksYLsCFy0Ej9WBTZndOrbRsY2ObXRst44jcvX3zQPwKzUGxL5z2rX1Z9PWh4xh-fYYxWQujeLy56ZSacQ3tI-Mgg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Retrospective analysis of adjuvant chemotherapy for curatively resected gastric cancer</title><source>MEDLINE</source><source>Baishideng "World Journal of" online journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Deng, Wei ; Wang, Qi-Wei ; Zhang, Xiao-Tian ; Lu, Ming ; Li, Jie ; Li, Yan ; Gong, Ji-Fang ; Zhou, Jun ; Lu, Zhi-Hao ; Shen, Lin</creator><creatorcontrib>Deng, Wei ; Wang, Qi-Wei ; Zhang, Xiao-Tian ; Lu, Ming ; Li, Jie ; Li, Yan ; Gong, Ji-Fang ; Zhou, Jun ; Lu, Zhi-Hao ; Shen, Lin</creatorcontrib><description>AIM:To determine the efficacy of adjuvant chemotherapy for gastric cancer in clinical practice,a retrospective analysis was conducted in a high-volume Chinese cancer center.METHODS:Between November 1995 and June 2007,a total of 423 gastric or esophagogastric adenocarcinoma patients who did(Arm A,n=300)or did not(Arm S,n=123)receive radical gastrectomy followed by postoperative chemotherapy were enrolled in this retrospective analysis.In Arm A,monotherapy(fluoropy rimidines,n=25),doublet(platinum/fluoropyrimidines,n=164),or triplet regimens[docetaxel/cisplatin/5FU(DCF),or modified DCF,epirubicin/cisplatin/5FU(ECF)or modified ECF,etoposide/cisplatin/FU,n=111]were administered.Disease-free survival(DFS)and overall survival(OS)were compared between the two arms.A subgroup analysis was carried out in Arm A.A multivariate analysis of prognostic factors was conducted.RESULTS:Stage?Ⅰ,ⅡandⅢcancers accounted for9.7%,35.7%and 54.6%of the cases,respectively,according to the American Joint Committee on Cancer(AJCC)staging system,7th edition.Only 178(42.1%)patients had more than 15 lymph nodes harvested.Hazard ratio estimates for Arm A compared with Arm S were 0.47(P&lt;0.001)for OS and 0.59(P&lt;0.001)for DFS.The 5-year OS rate was 52%in Arm A vs36%in Arm S(P=0.01);the adverse events in Arm A were mild and easily controlled.Ultimately,73 patients(26.5%)who received doublet or triplet regimens switched to monotherapy with fluoropyrimidines.The OS and DFS did not differ between monotherapy and the combination regimens,however,both were statistically improved in the subgroup of patients who were switched to monotherapy with fluoropyrimidines after doublet or triplet regimens as well as patients who received≥8 cycles of chemotherapy.CONCLUSION:In clinical practice,platinum/fluoropyrimidines with adequate treatment duration is recommended for stageⅡ/Ⅲgastric cancer patients accordingto the 7th edition of the AJCC staging system after curative gastrectomyeven with limited lymphadenectomy.</description><identifier>ISSN: 1007-9327</identifier><identifier>EISSN: 2219-2840</identifier><identifier>DOI: 10.3748/wjg.v20.i12.3356</identifier><identifier>PMID: 24696615</identifier><language>eng</language><publisher>United States: Baishideng Publishing Group Co., Limited</publisher><subject>Adenocarcinoma - drug therapy ; Adenocarcinoma - surgery ; Adjuvant ; Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Brief ; cancer ; chemotherapy ; Chemotherapy, Adjuvant - methods ; China ; Cisplatin - administration & dosage ; Cisplatin - therapeutic use ; Disease-Free Survival ; Epirubicin - therapeutic use ; Female ; Fluorouracil - administration & dosage ; Fluorouracil - therapeutic use ; Gastric ; Humans ; Kaplan-Meier Estimate ; Lymphadenecto ; Male ; Middle Aged ; Prognosis ; Retrospective Studies ; Stomach Neoplasms - drug therapy ; Stomach Neoplasms - surgery ; Taxoids - administration & dosage ; Treatment Outcome</subject><ispartof>World journal of gastroenterology : WJG, 2014-03, Vol.20 (12), p.3356-3363</ispartof><rights>2014 Baishideng Publishing Group Co., Limited. All rights reserved. 2014</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c440t-ee64509417e8209fa5bdadce9dab9dcf4904f5d22eabc958e6f963ba33e836783</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://image.cqvip.com/vip1000/qk/84123X/84123X.jpg</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3964407/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3964407/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24696615$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Deng, Wei</creatorcontrib><creatorcontrib>Wang, Qi-Wei</creatorcontrib><creatorcontrib>Zhang, Xiao-Tian</creatorcontrib><creatorcontrib>Lu, Ming</creatorcontrib><creatorcontrib>Li, Jie</creatorcontrib><creatorcontrib>Li, Yan</creatorcontrib><creatorcontrib>Gong, Ji-Fang</creatorcontrib><creatorcontrib>Zhou, Jun</creatorcontrib><creatorcontrib>Lu, Zhi-Hao</creatorcontrib><creatorcontrib>Shen, Lin</creatorcontrib><title>Retrospective analysis of adjuvant chemotherapy for curatively resected gastric cancer</title><title>World journal of gastroenterology : WJG</title><addtitle>World Journal of Gastroenterology</addtitle><description>AIM:To determine the efficacy of adjuvant chemotherapy for gastric cancer in clinical practice,a retrospective analysis was conducted in a high-volume Chinese cancer center.METHODS:Between November 1995 and June 2007,a total of 423 gastric or esophagogastric adenocarcinoma patients who did(Arm A,n=300)or did not(Arm S,n=123)receive radical gastrectomy followed by postoperative chemotherapy were enrolled in this retrospective analysis.In Arm A,monotherapy(fluoropy rimidines,n=25),doublet(platinum/fluoropyrimidines,n=164),or triplet regimens[docetaxel/cisplatin/5FU(DCF),or modified DCF,epirubicin/cisplatin/5FU(ECF)or modified ECF,etoposide/cisplatin/FU,n=111]were administered.Disease-free survival(DFS)and overall survival(OS)were compared between the two arms.A subgroup analysis was carried out in Arm A.A multivariate analysis of prognostic factors was conducted.RESULTS:Stage?Ⅰ,ⅡandⅢcancers accounted for9.7%,35.7%and 54.6%of the cases,respectively,according to the American Joint Committee on Cancer(AJCC)staging system,7th edition.Only 178(42.1%)patients had more than 15 lymph nodes harvested.Hazard ratio estimates for Arm A compared with Arm S were 0.47(P&lt;0.001)for OS and 0.59(P&lt;0.001)for DFS.The 5-year OS rate was 52%in Arm A vs36%in Arm S(P=0.01);the adverse events in Arm A were mild and easily controlled.Ultimately,73 patients(26.5%)who received doublet or triplet regimens switched to monotherapy with fluoropyrimidines.The OS and DFS did not differ between monotherapy and the combination regimens,however,both were statistically improved in the subgroup of patients who were switched to monotherapy with fluoropyrimidines after doublet or triplet regimens as well as patients who received≥8 cycles of chemotherapy.CONCLUSION:In clinical practice,platinum/fluoropyrimidines with adequate treatment duration is recommended for stageⅡ/Ⅲgastric cancer patients accordingto the 7th edition of the AJCC staging system after curative gastrectomyeven with limited lymphadenectomy.</description><subject>Adenocarcinoma - drug therapy</subject><subject>Adenocarcinoma - surgery</subject><subject>Adjuvant</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Brief</subject><subject>cancer</subject><subject>chemotherapy</subject><subject>Chemotherapy, Adjuvant - methods</subject><subject>China</subject><subject>Cisplatin - administration & dosage</subject><subject>Cisplatin - therapeutic use</subject><subject>Disease-Free Survival</subject><subject>Epirubicin - therapeutic use</subject><subject>Female</subject><subject>Fluorouracil - administration & dosage</subject><subject>Fluorouracil - therapeutic use</subject><subject>Gastric</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Lymphadenecto</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Stomach Neoplasms - drug therapy</subject><subject>Stomach Neoplasms - surgery</subject><subject>Taxoids - administration & dosage</subject><subject>Treatment Outcome</subject><issn>1007-9327</issn><issn>2219-2840</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkF1LwzAUhoMobk7vvZL8gc40X21uBBl-gSCIehtO09OuY2tn0k32783cHJqbEzjv8yY8hFymbCwymV9_zerxmrNxk_KxEEofkSHnqUl4LtkxGaaMZYkRPBuQsxBmjPEY4qdkwKU2WqdqSD5esfddWKLrmzVSaGG-CU2gXUWhnK3W0PbUTXHR9VP0sNzQqvPUrTxs4_MN9RgiiiWtIfS-cdRB69Cfk5MK5gEv9nNE3u_v3iaPyfPLw9Pk9jlxUrI-QdRSMSPTDHPOTAWqKKF0aEooTOkqaZisVMk5QuGMylFXRosChMBc6CwXI3Kz612uigVGsu09zO3SNwvwG9tBY_9v2mZq625thdHxB1ksYLsCFy0Ej9WBTZndOrbRsY2ObXRst44jcvX3zQPwKzUGxL5z2rX1Z9PWh4xh-fYYxWQujeLy56ZSacQ3tI-Mgg</recordid><startdate>20140328</startdate><enddate>20140328</enddate><creator>Deng, Wei</creator><creator>Wang, Qi-Wei</creator><creator>Zhang, Xiao-Tian</creator><creator>Lu, Ming</creator><creator>Li, Jie</creator><creator>Li, Yan</creator><creator>Gong, Ji-Fang</creator><creator>Zhou, Jun</creator><creator>Lu, Zhi-Hao</creator><creator>Shen, Lin</creator><general>Baishideng Publishing Group Co., Limited</general><scope>2RA</scope><scope>92L</scope><scope>CQIGP</scope><scope>W91</scope><scope>~WA</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20140328</creationdate><title>Retrospective analysis of adjuvant chemotherapy for curatively resected gastric cancer</title><author>Deng, Wei ; Wang, Qi-Wei ; Zhang, Xiao-Tian ; Lu, Ming ; Li, Jie ; Li, Yan ; Gong, Ji-Fang ; Zhou, Jun ; Lu, Zhi-Hao ; Shen, Lin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c440t-ee64509417e8209fa5bdadce9dab9dcf4904f5d22eabc958e6f963ba33e836783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adenocarcinoma - drug therapy</topic><topic>Adenocarcinoma - surgery</topic><topic>Adjuvant</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Brief</topic><topic>cancer</topic><topic>chemotherapy</topic><topic>Chemotherapy, Adjuvant - methods</topic><topic>China</topic><topic>Cisplatin - administration & dosage</topic><topic>Cisplatin - therapeutic use</topic><topic>Disease-Free Survival</topic><topic>Epirubicin - therapeutic use</topic><topic>Female</topic><topic>Fluorouracil - administration & dosage</topic><topic>Fluorouracil - therapeutic use</topic><topic>Gastric</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Lymphadenecto</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Stomach Neoplasms - drug therapy</topic><topic>Stomach Neoplasms - surgery</topic><topic>Taxoids - administration & dosage</topic><topic>Treatment Outcome</topic><toplevel>online_resources</toplevel><creatorcontrib>Deng, Wei</creatorcontrib><creatorcontrib>Wang, Qi-Wei</creatorcontrib><creatorcontrib>Zhang, Xiao-Tian</creatorcontrib><creatorcontrib>Lu, Ming</creatorcontrib><creatorcontrib>Li, Jie</creatorcontrib><creatorcontrib>Li, Yan</creatorcontrib><creatorcontrib>Gong, Ji-Fang</creatorcontrib><creatorcontrib>Zhou, Jun</creatorcontrib><creatorcontrib>Lu, Zhi-Hao</creatorcontrib><creatorcontrib>Shen, Lin</creatorcontrib><collection>中文科技期刊数据库</collection><collection>中文科技期刊数据库-CALIS站点</collection><collection>中文科技期刊数据库-7.0平台</collection><collection>中文科技期刊数据库-医药卫生</collection><collection>中文科技期刊数据库- 镜像站点</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>World journal of gastroenterology : WJG</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Deng, Wei</au><au>Wang, Qi-Wei</au><au>Zhang, Xiao-Tian</au><au>Lu, Ming</au><au>Li, Jie</au><au>Li, Yan</au><au>Gong, Ji-Fang</au><au>Zhou, Jun</au><au>Lu, Zhi-Hao</au><au>Shen, Lin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Retrospective analysis of adjuvant chemotherapy for curatively resected gastric cancer</atitle><jtitle>World journal of gastroenterology : WJG</jtitle><addtitle>World Journal of Gastroenterology</addtitle><date>2014-03-28</date><risdate>2014</risdate><volume>20</volume><issue>12</issue><spage>3356</spage><epage>3363</epage><pages>3356-3363</pages><issn>1007-9327</issn><eissn>2219-2840</eissn><abstract>AIM:To determine the efficacy of adjuvant chemotherapy for gastric cancer in clinical practice,a retrospective analysis was conducted in a high-volume Chinese cancer center.METHODS:Between November 1995 and June 2007,a total of 423 gastric or esophagogastric adenocarcinoma patients who did(Arm A,n=300)or did not(Arm S,n=123)receive radical gastrectomy followed by postoperative chemotherapy were enrolled in this retrospective analysis.In Arm A,monotherapy(fluoropy rimidines,n=25),doublet(platinum/fluoropyrimidines,n=164),or triplet regimens[docetaxel/cisplatin/5FU(DCF),or modified DCF,epirubicin/cisplatin/5FU(ECF)or modified ECF,etoposide/cisplatin/FU,n=111]were administered.Disease-free survival(DFS)and overall survival(OS)were compared between the two arms.A subgroup analysis was carried out in Arm A.A multivariate analysis of prognostic factors was conducted.RESULTS:Stage?Ⅰ,ⅡandⅢcancers accounted for9.7%,35.7%and 54.6%of the cases,respectively,according to the American Joint Committee on Cancer(AJCC)staging system,7th edition.Only 178(42.1%)patients had more than 15 lymph nodes harvested.Hazard ratio estimates for Arm A compared with Arm S were 0.47(P&lt;0.001)for OS and 0.59(P&lt;0.001)for DFS.The 5-year OS rate was 52%in Arm A vs36%in Arm S(P=0.01);the adverse events in Arm A were mild and easily controlled.Ultimately,73 patients(26.5%)who received doublet or triplet regimens switched to monotherapy with fluoropyrimidines.The OS and DFS did not differ between monotherapy and the combination regimens,however,both were statistically improved in the subgroup of patients who were switched to monotherapy with fluoropyrimidines after doublet or triplet regimens as well as patients who received≥8 cycles of chemotherapy.CONCLUSION:In clinical practice,platinum/fluoropyrimidines with adequate treatment duration is recommended for stageⅡ/Ⅲgastric cancer patients accordingto the 7th edition of the AJCC staging system after curative gastrectomyeven with limited lymphadenectomy.</abstract><cop>United States</cop><pub>Baishideng Publishing Group Co., Limited</pub><pmid>24696615</pmid><doi>10.3748/wjg.v20.i12.3356</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1007-9327 |
| ispartof | World journal of gastroenterology : WJG, 2014-03, Vol.20 (12), p.3356-3363 |
| issn | 1007-9327 2219-2840 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3964407 |
| source | MEDLINE; Baishideng "World Journal of" online journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Adenocarcinoma - drug therapy Adenocarcinoma - surgery Adjuvant Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Brief cancer chemotherapy Chemotherapy, Adjuvant - methods China Cisplatin - administration & dosage Cisplatin - therapeutic use Disease-Free Survival Epirubicin - therapeutic use Female Fluorouracil - administration & dosage Fluorouracil - therapeutic use Gastric Humans Kaplan-Meier Estimate Lymphadenecto Male Middle Aged Prognosis Retrospective Studies Stomach Neoplasms - drug therapy Stomach Neoplasms - surgery Taxoids - administration & dosage Treatment Outcome |
| title | Retrospective analysis of adjuvant chemotherapy for curatively resected gastric cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T22%3A38%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Retrospective%20analysis%20of%20adjuvant%20chemotherapy%20for%20curatively%20resected%20gastric%20cancer&rft.jtitle=World%20journal%20of%20gastroenterology%20:%20WJG&rft.au=Deng,%20Wei&rft.date=2014-03-28&rft.volume=20&rft.issue=12&rft.spage=3356&rft.epage=3363&rft.pages=3356-3363&rft.issn=1007-9327&rft.eissn=2219-2840&rft_id=info:doi/10.3748/wjg.v20.i12.3356&rft_dat=%3Cpubmed_cross%3E24696615%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/24696615&rft_cqvip_id=90888889504849524950485149&rfr_iscdi=true |